HMG-CoA還元酵素阻害薬BAY w 6228(Cerivastatin Sodium)の薬物動態と臨床試験成績 新規HMG-CoA還元酵素阻害薬BAY w 6228の臨床効果 4群間二重盲検法による用量設定試験
Pharmacokinetics and Clinical Studies of HMG-CoA Reductase Inhibitor BAY w 6228, Cerivastatin Sodium. Clinical Efficacy of a New HMG-CoA Reductase Inhibitor, BAY w 6228: A Dose-Finding Study among Four Groups by the Double Blind Method.